Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giacomo Sgalla

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Expert Opinion on Emerging Drugs|May 17, 2021
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trialsGiacomo Sgalla, Marialessia Lerede, Luca Richeldi
Expert Opinion on Drug Safety|April 21, 2021
An updated safety review of the drug treatments for idiopathic pulmonary fibrosisGiacomo Sgalla, Alessia Comes, Luca Richeldi
Respirology (Carlton, Vic.)|November 24, 2015
Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural historyGiacomo Sgalla, Alice Biffi, Luca Richeldi
Expert Opinion on Biological Therapy|October 5, 2023
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosisJacopo Simonetti, Giacomo Sgalla, Luca Richeldi
Expert Opinion on Biological Therapy|February 27, 2020
Antibody-based therapies for idiopathic pulmonary fibrosisGiacomo Sgalla, Mariachiara Flore, Matteo Siciliano, et al.
Expert Opinion on Investigational Drugs|January 24, 2023
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)Giacomo Sgalla, Jacopo Simonetti, Stefania Cortese, et al.
Expert Opinion on Emerging Drugs|November 13, 2023
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyondCarmelo Sofia, Alessia Comes, Giacomo Sgalla, et al.
Expert Opinion on Pharmacotherapy|December 15, 2021
Advances with pharmacotherapy for the treatment of interstitial lung diseaseAlessia Comes, Giacomo Sgalla, Alessandro Perrotta, et al.
Expert Opinion on Investigational Drugs|November 29, 2021
COVID-related fibrosis: insights into potential drug targetsGiacomo Sgalla, Alessia Comes, Marialessia Lerede, et al.
Journal of Medical Case Reports|July 9, 2016
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case reportStefania Cerri, Giacomo Sgalla, Luca Richeldi, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Expert Opinion on Emerging Drugs|May 17, 2021
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trialsGiacomo Sgalla, Marialessia Lerede, Luca Richeldi
Expert Opinion on Drug Safety|April 21, 2021
An updated safety review of the drug treatments for idiopathic pulmonary fibrosisGiacomo Sgalla, Alessia Comes, Luca Richeldi
Respirology (Carlton, Vic.)|November 24, 2015
Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural historyGiacomo Sgalla, Alice Biffi, Luca Richeldi
Expert Opinion on Biological Therapy|October 5, 2023
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosisJacopo Simonetti, Giacomo Sgalla, Luca Richeldi
Expert Opinion on Biological Therapy|February 27, 2020
Antibody-based therapies for idiopathic pulmonary fibrosisGiacomo Sgalla, Mariachiara Flore, Matteo Siciliano, et al.
Expert Opinion on Investigational Drugs|January 24, 2023
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)Giacomo Sgalla, Jacopo Simonetti, Stefania Cortese, et al.
Expert Opinion on Emerging Drugs|November 13, 2023
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyondCarmelo Sofia, Alessia Comes, Giacomo Sgalla, et al.
Expert Opinion on Pharmacotherapy|December 15, 2021
Advances with pharmacotherapy for the treatment of interstitial lung diseaseAlessia Comes, Giacomo Sgalla, Alessandro Perrotta, et al.
Expert Opinion on Investigational Drugs|November 29, 2021
COVID-related fibrosis: insights into potential drug targetsGiacomo Sgalla, Alessia Comes, Marialessia Lerede, et al.
Journal of Medical Case Reports|July 9, 2016
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case reportStefania Cerri, Giacomo Sgalla, Luca Richeldi, et al.
Pageof 5